|
|
| | 2-[((2',6'-DICHLORO-4'-HYDROXY)PHENYL)AMINO]BENZENEACETIC ACID Basic information |
| | 2-[((2',6'-DICHLORO-4'-HYDROXY)PHENYL)AMINO]BENZENEACETIC ACID Chemical Properties |
| Melting point | 178-185°C dec. | | Boiling point | 432.7±45.0 °C(Predicted) | | density | 1.520±0.06 g/cm3(Predicted) | | Fp | 2℃ | | storage temp. | -20°C | | solubility | Soluble in DMSO, ethanol or methanol | | pka | 4.17±0.10(Predicted) | | form | Solid | | color | White to off-white | | BRN | 4198042 | | Stability: | Light Sensitive | | Major Application | clinical testing | | InChI | 1S/C14H11Cl2NO3/c15-10-6-9(18)7-11(16)14(10)17-12-4-2-1-3-8(12)5-13(19)20/h1-4,6-7,17-18H,5H2,(H,19,20) | | InChIKey | KGVXVPRLBMWZLG-UHFFFAOYSA-N | | SMILES | OC(=O)Cc1ccccc1Nc2c(Cl)cc(O)cc2Cl |
| Hazard Codes | T,N,Xn,F | | Risk Statements | 25-37/38-41-50/53-36-20/21/22-11 | | Safety Statements | 26-39-45-60-61-36/37-16 | | RIDADR | UN 2811 6.1/PG 3 | | WGK Germany | 3 | | RTECS | AG6542800 | | HazardClass | 6.1 | | Storage Class | 3 - Flammable liquids | | Hazard Classifications | Acute Tox. 4 Dermal Acute Tox. 4 Inhalation Acute Tox. 4 Oral Eye Irrit. 2 Flam. Liq. 2 |
| | 2-[((2',6'-DICHLORO-4'-HYDROXY)PHENYL)AMINO]BENZENEACETIC ACID Usage And Synthesis |
| Description | 4-hydroxy Diclofenac is a CYP2C9 metabolite of the NSAID diclofenac . By inhibiting COX and subsequently suppressing PGE2 synthesis, it demonstrates anti-inflammatory and analgesic properties. | | Chemical Properties | Light Violet Solid | | Uses | A metabolite of Diclofenac, a nonsteroidal inflammatory compound and cyclooxygenase (COX) inhibitor. | | Uses | A metabolite of Diclofenac, a nonsteroidal anti-inflammatory compound and cyclooxygenase (COX) inhibitor | | Uses | A Cytochrome P450 2C9 (CYP2C9) metabolite of diclofenac | | Definition | ChEBI: An monocarboxylic acid that is the 4'-hydroxylated metabolite of diclofenac. | | General Description | 4′-Hydroxydiclofenac is one of the metabolites of diclofenac, a nonsteroidal anti-inflammatory drug (NSAID) used in human and veterinary medicine. | | References | [1] R J SAWCHUK. Analysis of diclofenac and four of its metabolites in human urine by HPLC.[J]. Pharmaceutical Research, 1995, 12 5: 756-762. DOI: 10.1023/a:1016276012891 [2] ü. YAAR. The role of CYP2C9 genotype in the metabolism of diclofenac in vivo and in vitro[J]. European Journal of Clinical Pharmacology, 2001, 57 1: 729-735. DOI: 10.1007/s00228-001-0376-7 [3] R YAMAZAKI. Hydrolytic activity is essential for aceclofenac to inhibit cyclooxygenase in rheumatoid synovial cells.[J]. Journal of Pharmacology and Experimental Therapeutics, 1999, 289 2: 676-681.
[4] FENG ZHANG. Inhibition of drug-metabolizing enzymes by Jingyin granules: implications of herb–drug interactions in antiviral therapy[J]. Acta Pharmacologica Sinica, 2021, 43 4: 1072-1081. DOI: 10.1038/s41401-021-00697-2 |
| | 2-[((2',6'-DICHLORO-4'-HYDROXY)PHENYL)AMINO]BENZENEACETIC ACID Preparation Products And Raw materials |
|